MRSA Drugs Companies

Disclaimer: List of key companies in no particular orderLatest MRSA Companies Update

• 
  June 2023: Drugmaker Sanofi called the rival pharmaceutical company's court filing "improper" in a battle over the retail market for the EpiPen auto-injector device, and on Wednesday, the U.S. judge granted Sanofi's request to limit Mylan's attempt to recoup litigation costs in an antitrust complaint. After successfully fending Sanofi's accusations, Mylan—now a part of the Pennsylvania-based healthcare corporation Viatris—requests reimbursement for litigation expenditures. The disagreement will now be heard in federal court, according to the two companies, which claimed they could not agree over costs.

• 
  Oct 2023: At its location in Settimo, Italy, Olon Biotech, a branch of the Italian API manufacturer Olon, has opened a new facility for the large-scale synthesis of proteins from alternative sources. Olon estimated that the new plant would cost €70 million to build. Since alternative proteins are employed in many non-animal, non-vegetable product categories, such as food and drinks, they are considered extremely sustainable and do not affect the environment. The company has announced a significant investment plan to modernize and expand its facilities, which create active substances using cutting-edge, environmentally friendly biotechnological techniques.

• Merck KGaA (UK)


• Olon (Italy)


• Allergan (Dublin, Ireland)


• Baxter (US)


• Theravance Biopharma (Theravance Biopharma)


• Pfizer (US)


• Mylan NV (US)


• Novartis (Switzerland)